HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT
Abroad (travel likely)RecruitingEARLY_PHASE1
Conditions
Hematologic Malignancy
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Duke University Health System, Durham, North Carolina, United States
Study leads
Sanghee Hong, MD
Principal Investigator
Duke Health